CJC-1295 No DAC (Modified GRF 1-29)

+ Free Shipping

CJC-1295 No DAC (Modified GRF 1-29) is a GHRH analogue that stimulates pulsatile growth hormone release from the pituitary. Supplied as a 5mg lyophilised vial. ≥99% purity. For research use only.

SKU: ANX-CJC-5 Category: Tag:
Guaranteed Safe Checkout

CJC-1295 No DAC (Modified GRF 1-29) — Research Grade | 5mg

CJC-1295 No DAC, also designated Modified GRF(1-29), is a synthetic analogue of growth hormone-releasing hormone (GHRH). Unlike the DAC (Drug Affinity Complex) variant, the no-DAC form retains a shorter half-life of approximately 30 minutes, producing sharp, pulsatile GH release that more closely mimics the body’s natural secretion pattern. This characteristic makes it particularly well-suited for research examining pulsatile GH dynamics.

In research contexts, CJC-1295 No DAC has been studied for its effects on pituitary somatotroph stimulation, GH pulse amplitude, IGF-1 elevation, and downstream metabolic effects including lean mass accretion, fat metabolism, and tissue repair pathways. It is frequently investigated in combination with a GHRP such as ipamorelin, which acts via a complementary ghrelin receptor pathway — the synergy between these two compounds is well-documented in the literature.

AuroraNX supplies CJC-1295 No DAC as a 5mg lyophilised powder vial. Reconstitute with bacteriostatic water prior to use. Store at 2–8°C.

Specifications

  • Peptide: Modified GRF(1-29) / CJC-1295 No DAC
  • Purity: ≥99% (HPLC verified, COA available)
  • Form: Lyophilised powder
  • Vial size: 5mg
  • Storage: Refrigerate at 2–8°C
Research Use Disclaimer This product is supplied exclusively for in vitro research and laboratory purposes. It is not intended for human or animal consumption, therapeutic use, or self-administration. AuroraNX does not provide medical advice. This product has not been evaluated or approved by the TGA. By purchasing, the buyer confirms they are a qualified researcher and agrees to AuroraNX Terms of Use.